Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Deferred Tax Liability: 2010-2024

Historic Non-Current Deferred Tax Liability for Ligand Pharmaceuticals (LGND) over the last 12 years, with Dec 2024 value amounting to $32.5 million.

  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability fell 51.14% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year decrease of 51.14%. This contributed to the annual value of $32.5 million for FY2024, which is 58.02% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Non-Current Deferred Tax Liability is $32.5 million, which was down 58.02% from $77.5 million recorded in FY2023.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability's 5-year high stood at $124.3 million during FY2020, with a 5-year trough of $32.5 million in FY2024.
  • Its 3-year average for Non-Current Deferred Tax Liability is $61.9 million, with a median of $75.6 million in 2022.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first soared by 140.40% in 2020, then crashed by 58.02% in 2024.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability (Yearly) stood at $124.3 million in 2020, then slumped by 41.83% to $72.3 million in 2021, then grew by 4.53% to $75.6 million in 2022, then rose by 2.50% to $77.5 million in 2023, then slumped by 58.02% to $32.5 million in 2024.